ArticleJACC. Case reports2025
Bioprosthetic Valve Failure: Management Strategies in the Mitral Position.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBioprosthetic valve failure is a growing clinical challenge, particularly in younger patients with comorbidities. Transcatheter valve-in-valve implantation is an alternative to redo surgery but may fail in cases of severe calcification or infection. CASE SUMMARY: A 37-year-old man with systemic lupus erythematosus and end-stage renal disease on hemodialysis presented with NYHA functional class III dyspnea. He had undergone mitral valve replacement (MVR) with a bioprosthetic valve 12 years before, followed by transcatheter mitral valve-in-valve (ViV) implantation 9 years later. Two years post-ViV, he developed recurrent severe mitral stenosis with a mean gradient of 24 mm Hg, extensive mitral annular calcification, and severe pulmonary hypertension. DISCUSSION: Bioprosthetic valve failure represents a significant challenge in clinical practice, especially in patients with multiple comorbidities or prior interventions. This case demonstrates the progression from surgical bioprosthetic MVR to transcatheter ViV implantation and ultimately redo surgery. TAKE-HOME MESSAGES: This case highlights that optimal management of bioprosthetic mitral valve failure requires individualized, multidisciplinary decision-making. Surgical re-intervention remains essential for patients with severe annular calcification or complications after transcatheter procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.